Lorraine M Posobiec (L M Posobiec, Lorraine Posobiec)

Years Active: 2019-2023
Publications (10 Years): 5

GlaxoSmithKline USA

This page only lists publications with an associated author ORCID identifier.

Affiliation History

GlaxoSmithKline USA

United States

Study Manager :: Reproductive Toxicology

Publications

Lorraine M Posobiec, C Kopp, S M Murzyn, T Olitan, J Rendemonti, J French, E Tamborini, J Campey, M Longo, T Danberry, M Vaillancourt, W Nowland, M Daoud, C Qualls, S B Harris
Harmonization of criteria and terminology in fetal rat skeletal evaluations. Birth defects research (2023)
Lorraine M Posobiec
Author reply to Copp et al. (2022) correspondence. Birth defects research 114 (12) (2022)
Lorraine M Posobiec, Sharon P Chapman, Stacia F Murzyn, Joyce E Rendemonti, Dinesh J Stanislaus, Elizabeth H Romach
No developmental toxicity observed with dolutegravir in rat whole embryo culture. Birth defects research 113 (16) (2021)
Lorraine M Posobiec, Susan B Laffan
Dose range finding approach for rodent preweaning juvenile animal studies. Birth defects research 113 (5) (2020)
Dinesh J Stanislaus, Lorraine M Posobiec, Susan B Laffan, Howard M Solomon, Mary K Ziejewski, Elizabeth H Romach
Absence of developmental and reproductive toxicity in animals exposed to dolutegravir. Birth defects research 112 (3) (2019)

Lorraine M Posobiec.css-eqlu8i{font-size:small;padding-left:4px;} (L M Posobiec, Lorraine Posobiec)